Long term outcome of Permanent Alopecia after Taxotere
Fosamax (alendronate) is a widely prescribed bisphosphonate medication used to treat osteoporosis and other bone conditions. However, since its approval in 1995, post-marketing surveillance and clinical studies have identified a rare but serious adverse event associated with long-term use: osteonecrosis of the jaw (ONJ). This condition involves the death of bone tissue in the jaw, often leading to pain, infection, and exposed bone. The U.S. Food and Drug Administration (FDA) has issued multiple safety communications regarding this risk, particularly for patients who have used Fosamax for extended periods or who undergo invasive dental procedures while on the drug.
This article reviews the medical evidence linking Fosamax to ONJ, outlines key safety considerations, and provides practical guidance for patients who may have been affected. This content is for informational and advertising purposes only. It does not constitute medical or legal advice, and does not create an attorney-client relationship.
Medical Evidence: Bisphosphonates and Osteonecrosis of the Jaw
The association between nitrogen-containing bisphosphonates—including alendronate (Fosamax), risedronate, and ibandronate—and ONJ has been documented in peer-reviewed literature. A 2009 review in Bone examined bisphosphonate-associated adverse events and confirmed that oral bisphosphonates used for osteoporosis have been linked to ONJ, along with gastrointestinal issues, musculoskeletal pain, and ocular events. The review noted that intravenous bisphosphonates used in oncology carry a higher risk, but oral formulations are not without concern.
"Oral bisphosphonates (alendronate, risedronate and ibandronate), mainly used for the treatment of osteoporosis, have been associated with adverse events from the upper gastrointestinal tract, acute phase response, hypocalcaemia and secondary hyperparathyroidism, musculoskeletal pain, osteonecrosis of the jaw and ocular events."
Source: PubMed ID 19570737, Bisphosphonate-associated adverse events, 2009.
Further research published in the Journal of Clinical Endocrinology & Metabolism (2010) highlighted that bisphosphonates accumulate in bone and are released for months or years after treatment stops. This pharmacokinetic property raises questions about optimal treatment duration, especially given the emergence of rare side effects like ONJ that were not fully apparent in initial clinical trials.
Large database studies have attempted to quantify ONJ incidence. A 2010 review in Current Opinion in Rheumatology analyzed health database findings and reported that while some studies found no increase in jaw surgery for inflammatory conditions (a proxy for ONJ), the evidence remains mixed. The authors emphasized that definitive conclusions require larger, X-ray-adjudicated studies.
Evidence Table: Key Studies on Fosamax and ONJ
| Study / Source | Population | Key Finding |
|---|---|---|
| Bisphosphonate-associated adverse events (PubMed 19570737, 2009) | Patients on oral bisphosphonates (alendronate, risedronate, ibandronate) | ONJ identified as a known adverse event; risk lower than with IV bisphosphonates but clinically significant. |
| Long-term use of bisphosphonates in osteoporosis (PubMed 20173017, 2010) | Osteoporosis patients on alendronate for up to 10 years | Good tolerability and safety in long-term studies, but rare side effects like ONJ emerged post-approval. |
| Bisphosphonate adverse effects, lessons from large databases (PubMed 20473174, 2010) | Osteoporosis patients in registry studies | No definitive increase in jaw surgery for ONJ was confirmed, but studies were limited by size and lack of X-ray confirmation. |
Practical Checklist for Patients Concerned About Fosamax and ONJ
If you have taken Fosamax (alendronate) and are experiencing jaw symptoms, or if you are planning dental work, consider the following steps. This checklist is not a substitute for professional medical advice.
- Review your medication history: Note the duration of Fosamax use, dosage, and any other bisphosphonates (e.g., Actonel, Boniva, Reclast) you may have taken.
- Monitor for symptoms: Watch for jaw pain, swelling, numbness, loose teeth, or exposed bone in the mouth—especially after dental extractions or implants.
- Consult your dentist and physician: Inform both your dentist and prescribing doctor about your Fosamax use. A dental exam and imaging (e.g., panoramic X-ray) may be recommended.
- Consider a drug holiday: Some guidelines suggest pausing bisphosphonate therapy before invasive dental procedures, but this decision must be made by your healthcare provider.
- Document your medical records: Keep copies of prescriptions, dental records, and any diagnostic reports related to jaw issues.
- Seek a second opinion: If you are diagnosed with ONJ, consider consulting an oral surgeon or a specialist in metabolic bone disease.
Legal Context and Causation Considerations
Legal claims involving Fosamax and ONJ often hinge on proving causation—that the drug directly caused the jaw injury. Courts have examined this issue in various contexts, including mass tort litigation. While the FDA has updated Fosamax labeling to include ONJ warnings, causation remains a complex medical and legal question. Each case depends on individual factors such as duration of use, dental history, and other risk factors (e.g., cancer, chemotherapy, corticosteroid use).
This article does not promise compensation, representation, or any specific legal outcome. It is not legal advice. If you believe you have suffered ONJ related to Fosamax, you should consult with a qualified attorney who can evaluate the merits of your potential claim.
Medical and Legal Disclaimers
Medical Disclaimer: The information provided here is for general informational purposes only and does not constitute medical advice. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or treatment. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
Legal Disclaimer: This content is an advertisement for legal services. It does not create an attorney-client relationship. The information presented is not legal advice. You should not act or refrain from acting based on any information provided here without first seeking appropriate legal counsel. Prior results do not guarantee a similar outcome.
Request a Free Case Review
If you or a loved one has been diagnosed with osteonecrosis of the jaw after taking Fosamax (alendronate), you may have legal rights. Our team is available to review your situation at no cost and with no obligation. Contact patient-physician.com today to speak with a representative about your potential case.
Call us or submit an online inquiry to request a free, confidential case review.